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Abstract
Background Since 2005 an interdisciplinary German
apheresis working group has been established by mem-
bers of both German Societies of Nephrology and of
Lipidologists and completed the data set for the registry
according to the current guidelines and the German indica-
tion guideline for apheresis in 2009. In 2011 the German
Lipoprotein Apheresis Registry (GLAR) was launched and
data are available over nearly 5 years now.
Methods and results During the time period 2012–2016,
71 German apheresis centers collected retrospective and
prospective observational data of 1435 patients undergo-
ing lipoprotein apheresis (LA) treatment of high LDL-C
levels and/or high Lp (a) levels suffering from cardiovascu-
lar disease (CVD) or progressive CVD. A total of 15,527
completely documented LA treatments were entered into
the database. All patients treated by LA showed a median
LDL-C reduction rate of 67.5%, and a median Lp (a) re-
duction rate of 71.1%. Analog to the Pro(a)LiFe pattern,
patient data were analyzed to the incidence rate of coro-
nary events (MACE) 1 and 2 years before the beginning
of LA treatment (y-2 and y-1) and prospectively two years
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on LA treatment (y + 1 and y + 2). During two years of
LA treatment a MACE reduction of 78% was observed. In
the years considered, side effects of LA treatment were low
(5.9%) and mainly comprised puncture problems.
Conclusions The data generated by the GLAR shows that
LA lowers the incidence rate of cardiovascular events in
patients with high LDL-C and/or high Lp (a) levels, pro-
gressive CVD, and maximally tolerated lipid lowering med-
ication. In addition, LA treatments were found to be safe
with a low rate of side effects.
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Introduction
Up to the early 80s of the last century, no adequate lipid
lowering therapy was available for patients suffering from
progressive cardiovascular diseases induced by severe hy-
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perlipidemia, mainly high LDL-cholesterol (LDL-C) levels
or Lp (a)-hyperlipoproteinemia (Lp (a)-HLP (a)) [1]. Since
then, lipoprotein apheresis (LA) has been developed to treat
a subset of these patients [2]. During the 80s and 90s many
trials with respect to therapy by different statins were per-
formed. They showed that in patients suffering from severe
hypercholesterolemia a decrease of LDL-C is associated
with a decrease of cardiovascular events in both primary and
secondary prevention [3]. However, for LA patients with
cardiovascular disease (CVD) suffering from high LDL-C
and/or Lp (a) levels only a few studies are available demon-
strating an additional LA effect on cardiovascular risk re-
duction [4–6]. In the 2000s the Federal Joint Committee
(G-BA), a paramount decision-making body of the German
healthcare system, called for a reassessment of the approval
of chronic LA therapy for regular reimbursement. At the
same time an interdisciplinary German apheresis working
group was established by members of both German Soci-
eties of Nephrology and Lipidologists, who developed an
indication for LA with respect to current cardiovascular
guidelines and scientific knowledge and initiated the es-
tablishment of the German Lipoprotein Apheresis Registry
(GLAR) [7, 8]. GLAR was launched in 2011 [9, 10] and
data collected over almost 5 years are available.
Materials and methods
Access to the German Lipoprotein Apheresis Registry
(GLAR)
Before an apheresis center is eligible to enter patient data
into the database, an application has to be filed with the
Stiftung für Nephrologie e. V. (Foundation for Nephrology,
founded by Verband Deutsche Nierenzentren, Duesseldorf,
Germany). A cooperation agreement between the above-
named foundation and the respective apheresis center is
then concluded. Amongst other things this document clar-
ifies data security aspects and reporting duties of the re-
sponsible body (foundation). After signing the agreement,
the apheresis center is assigned a center key in form of
a unique number. Only the foundation has knowledge of
the associated center name, but not the technical service
provider, BioArtProducts (B.A.P., Rostock, Germany). The
foundation announces new participating centers to the ser-
vice provider in an anonymized form providing the center
key. Subsequently, B.A.P. creates login credentials for the
online platform (https://apherese-register.org) and provides
these to the foundation who in turn forwards them to the
participating center. Only then is the center enabled to par-
ticipate in the GLAR via the online platform.
Current German data protection laws require all partici-
pating patients of the respective apheresis centers to provide
written informed consent to participation in the GLAR prior
to any pseudonymized data being entered into the registry.
The consent declarations are archived by the respective cen-
ter. Analog to the indexing of centers, all patients are as-
signed a key in form of a unique number issued by their
treating apheresis center. This ensures that only the treating
center is able to link patient identity to patient data via the
patient key.
The foundation as the responsible body has assigned the
Institute for Nephrology (WiNe) with the operation of the
registry.
Data base and data quality
The database is developed in MySQL (Cupertino, Califor-
nia, USA) with GlassFish (Oracle Corporation, Redwood
City, California) as server technology running on an Ubuntu
system (Linux operating system, Canonical Ltd, UK). High
data quality is supported by programmed range checks, va-
lidity checks, and consistency checks of the data entered.
Data entry
Once access to GLAR is initiated, every patient’s data is
handled like an electronic medical file containing e. g. med-
ical history, relevant family history, diagnoses, medications,
laboratory results, and side effects of apheresis treatments.
The scientific board of the GLAR requests quarterly doc-
umentation of a representative LA treatment including all
lipid parameters before and after the treatment procedure
and progress of any vascular diseases, e. g. coronary heart
disease, stroke, as well as side effects associated with the
LA treatment. Changes in lipid-lowering therapy strategy
and reasons for patients to drop out of the registry are doc-
umented promptly.
Data queries and evaluation
The latest database query for this publication was per-
formed in November 2016. All data were collected in the
time period 2012–2016 (until October 2016) and analyzed
using the statistics software SigmaStat (SigmaStat 4.0; Sys-
tat Software Inc., San Jose, California, USA).
Additionally, patient data were analyzed with respect to
incidence rates of major coronary events (MACE) and ma-
jor non-coronary events (MANCE) 1 and 2 years before
(y-2 and y-1) and prospectively 1 and 2 years after initia-
tion of LA treatment (y + 1 and y + 2). This current data
pattern gives the optimal sample size for statistical evalu-
ation. MACE was defined as an outcome parameter, i. e.,
cardiovascular death, nonfatal myocardial infarction, coro-
nary bypass surgery, percutaneous coronary intervention, or
stent, whereas MANCE was determined as non-cardiovas-
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Table 1 Age and sex distribution in the GLAR database (data
interrogation until 2015)
Age Males Females Total
Under 18
18–30 3 4 7
30–39 6 21 27
40–49 23 88 111
50–59 105 231 336
60–69 127 256 383
70 and older 177 238 415
Total 441 838 1279
Oldest patient 90 years old
Youngest patient 20 years old
cular events i. e. stroke, carotid percutaneous transluminal
angioplasty or carotid surgery or peripheral vascular events
(peripheral vascular event of lower extremities or renal ar-
teries = percutaneous transluminal angioplasty, stent, by-
pass surgery, amputation), or venous thrombotic events =
deep venous thrombosis or pulmonary embolism.
Results
Data of more than 19,800 LA treatments of 1435 patients
were entered into GLAR, mostly 1-2 treatments per quarter.
With more than 78% of the final documentation forms being
complete 15,527 LA treatments were finally analyzed. All
required data are available for each patient as the design of
the entry form requires a complete data collection.
From 2012 to 2016, 71 German apheresis centers col-
lected retrospective and prospective observational data of
1435 patients undergoing LA to treat high LDL-C levels
and/or high Lp (a) levels, who were suffering from progres-
sive cardiovascular disease (CVD). Until 2015 the majority
of patients were female (838 females vs 441 males) with
most of them being 60 years or older (Table 1).
To qualify for reimbursement of LA therapy the German
guideline for LA treatment requests Lp (a) levels above
60 mg/dl (120 nmol/l) and normal LDL levels (mainly
<100 mg/dl) in addition to clinical features. Therefore, we
analyzed the data for those levels.
Table 2 Top 5 of side effects documented in the GLAR between 2012 and 2015
Year 2012 2013 2014 2015
Treatments per year 1674 3181 5007 5305
Puncture problems 14 (0.84%) 51 (1.6%) 99 (1.98%) 150 (2.83%)
Hypotension 17 (1.02%) 26 (1.28%) 64 (1.28%) 58 (1.09%)
Unclassified effects 10 (0.6%) 15 (0.47%) 33 (0.66%) 48 (0.9%)
Technical failures 7 (0.42%) 6 (0.19%) 21 (0.42%) 35 (0.66%)
Dizziness 1 (0.06%) 8 (0.25%) 23 (0.46%) 20 (0.38%)
Total 49 (3.0%) 106 (3.3%) 240 (4.8%) 311 (5.9%)
Until 2015 with respect to the patient population of the
GLAR, 50.8% (n = 544) of the included patients had Lp (a)
levels ≥60 mg/dl (≥120nmol/l), 23.3% (n = 325) LDL-C
levels ≥100 mg/dl (≥2.6mmol/l), and in 51.5% (n = 551)
both levels (Lp(a) levels ≥30mg/dl (≥70nmol/l); LDL-C
levels ≥100mg/dl (≥2.6mmol/l)) were elevated despite
maximally tolerated cholesterol lowering drug therapy.
All patients were treated by LA with a median acute
LDL-C reduction rate of 68.6%, and median acute Lp (a)
reduction rate of 70.4%. The detailed median annual reduc-
tion rates of LDL-C levels were 68.5% (n = 449) in 2012,
68.7% (n = 695) in 2013, 68.7% (n = 916) in 2014, and
67.5% (n = 1070) in 2015. The median annual reduction
rates of Lp (a) levels were 68.8% (n = 449) in 2012, 69.6%
(n = 695) in 2013, 71.3% (n = 916) in 2014, and 71.1%
(n = 1070) in 2015.
The rate of LA treatment side effects remained low
(ca. 5%) (mainly puncture problems) during the observed
years (Table 2).
Analog to the pattern of the Pro(a)LiFe study, patient
data were analyzed with respect to incidence rates of ma-
jor coronary events (MACE) 1 and 2 years before (y-2 and
y-1) and prospectively two years on LA treatment (y + 1
and y + 2). Patients with available data according to the
query pattern (data points for y-2, y-1 and y + 1, y + 2 in
the period 2012–2016) were found to have a reduction in
MACE of 77% (Fig. 1). The same query scheme was ap-
plied for major non-coronary events (MANCE) (Fig. 2). An
average reduction rate of MANCE of 71% was observed.
For both, MACE and MANCE, the above detailed data
were available for varying numbers of patients over the
years. Therefore, events are presented as median over the
entire time interval 2012–2015 (Figs. 1 and 2).
Discussion
In 2000s the Federal Joint Committee (G-BA) called for
the collection of clinical outcome data from patients under-
going regular LA therapy. At the same time an apheresis
working group was founded in order to create an LA reg-
istry (GLAR). With respect to other international and na-
tional apheresis registries, this is the first registry to record
K
The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on 47
Fig. 1 Major Coronary Events
(MACE) 1 and 2 years before
(y-2 and y-1) and two years on
LA treatment (y + 1 and y + 2).
GLAR data interrogation 2012
and 2013, in which these event
patterns can be found
such a large amount of LA treatments and LA patients [11,
12]. After encouraging preliminary results, we now report
on an analysis of data collected over almost 5 years [9].
The GLAR represents a multi-center acquisition of data
of more than 15,000 single LA treatments, which to the best
knowledge of the authors is the highest number of cases
collected world-wide. The data prove a very high quality of
treatment with respect to the reduction of LDL-C and Lp (a)
levels and underline the potency of LA as therapeutic means
for patients suffering from, in parts multiple, cardiovascular
events.
This result was obtained with a low number of docu-
mented non serious side effects like hypotension which is
a potential side effect of extracorporeal therapies in gen-
eral and not specific to LA treatment. The most common
side effects not related to the procedure were issues with
punctures. The light increase of puncture problems may
be explained by the increase of new patients documented
in GLAR. In the last four years very few drop-outs were
observed (on average 30 patients per year; 4.3% of all pa-
tients) from GLAR, mainly patient-initiated (41%) or death
(30%).
Following the pattern of the Pro(a)LiFe-study, an ad-
ditional evaluation of coronary events (MACE) and non-
coronary events (MANCE) two (y-2) and one year (y-1)
prior to LA treatment as well as two years on LA treat-
ment (y + 1 and y + 2) was performed. It is noteworthy
that the impressive reductions are consistent with the data
of the Pro(a)LiFe-study. Reduction rates of MACE (–72
and –78%, respectively), MANCE (–71 and –75.9%, re-
spectively) were striking already in the first year after the
onset of LA [5]. We assume that the events documented
here are potentially comparable as well to data on survival
rates reported by the Pro(a)LiFe-study [5, 13]. However,
it has to be kept in mind that the reported data are based
on entries in the GLAR, only. As the registry is based on
voluntary participation, limitations to documentation qual-
ity, completeness of data, and regularity of data recordings
do exist. Additionally, the number of participating aphere-
sis centers remained nearly constant in the last two years.
This might be beneficial for the data quality due to the
more experienced staff of those centers. Nonetheless, more
efforts should be done to increase the number of participat-
ing apheresis centers to support the concept of GLAR as
a representative LA database of Germany. Since the term
of GLAR is currently extended to 2019 at least, through-
out the next years data of LA patients covering longer in-
tervals will become available. As in the follow-up of the
recently published Pro(a)LiFe-study, evaluations of MACE
and MANCE rates of patients undergoing LA treatment for
3, 4, or 5 years will be possible [14].
Moreover, the new PCSK9-inhibitors show promising
effects on the lipid status of patients currently receiving LA
treatment. In the currently documented apheresis treatments
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Fig. 2 Major Non-Coronary
Events (MANCE) reduction
rate 1 and 2 years before (y-2
and y-1) and two years on LA
treatment (y + 1 and y + 2).
GLAR data interrogation 2012
and 2013, in which these event
patterns can be found
of patients with elevated LDL-C levels these substances
so far have not shown to have an effect on participation
rates and/or discontinuation of apheresis therapy [15]. This
is likely to change in 2016/2017 as in the meantime two
PCSK9-inhibitors have been approved by the BfArM.
Due to the high LDL-C level lowering potential of
PCSK9-inhibitors, a certain number of patients are ex-
pected to do without LA treatment. The recently published
ODYSSEY ESCAPE trial showed a discontinuation in
63.4% of patients on alirocumab who were previously
undergoing regular LA [15]. However, according to the
study design the reason for stopping LA was not a sat-
isfactory LDL-C level but a general reduction of 30% of
the pre-LA LDL-C level. 36.6% of patients had to con-
tinue LA procedure. In addition, in some patients with
discontinued LA treatment LDL-C increased again at lev-
els, which were higher than the requested target levels
for LDL-C by guidelines. Since clinical decision-making
is based on target levels GLAR will give insights of the
effects of PCSK9-inhibitors in real life. To this point, no
end-point studies exist which would allow to justify the
broad use of PCSK9-inhibitor therapy in patients currently
undergoing LA treatment [16] and suffering from, often
multiple, cardiovascular events. Furthermore, it has to be
emphasized that for patients with elevated Lp (a) levels
(>60 mg/dl; >120 nmol/l) there is to date no alternative to
a continued regular LA treatment [17]. In other patients,
the new and promising PCSK9-inhibitor therapy may allow
to reduce LDL-C concentration to a target value <70 mg/dl
(<1.8mmol/l) for the very first time [17], either as single
therapy or in combination with statin medication and LA
treatment. An additional focus of the GLAR for the com-
ing years will be to observe if PCSK9-inhibitors will allow
stopping or even preventing a progress of cardiovascular
disease either as single therapy or in combination with
other therapies. The GLAR will play an important role
for generating evidence with respect to novel pharmaco-
logical developments, such as PCSK9-inhibitors, and their
therapeutic potential, as well as their different capabilities
compared to LA treatment.
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